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Introduction: Among the more than 100 types of human papillomavirus (HPV), about 90% of genital warts
are caused by HPV types 6 and 11; types 16 and 18 cause 70% of cases of cervical cancer. Tracking through
Pap associated with condom use are strategies in preventing this condition. Vaccination against HPV has
been added to the portfolio of protection. In September 13, 2010, the quadrivalent vaccine against HPV
was made available for resident girls between 11 and 15 years of age in the municipality of Campos
dos Goytacazes, Rio de Janeiro, Brazil using a hybrid strategy of vaccination.
Objectives: Assess vaccination coverage in that municipality after adopting several strategies for active
search and missed opportunities for vaccination against HPV. Evaluate acceptance for the vaccine and
reasons for refusal the HPV vaccine. Evaluate the frequency and occurrence of adverse events to that vac-
cine. A survey of reduction of genital warts was also conducted.
Methods: A survey of vaccination coverage for the chosen age group was carried out. By previous appoint-
ment, schools received vaccination on site; two ‘‘D-Days’’ formunicipal vaccinationwere set along sidewith
thecreationof theproject ‘‘HolidaysHPV-free’’. Thevaccinewasalsooffered in twopublicpermanent siteson
adailybasis;Vaccineadverseeventswere assessed in1000adolescents after96 hofvaccineadministrationA
survey on reduction of genital warts was studied 3 years before and 2 years after introduction of vaccine.
Results: The1st vaccine dose reached about 53%, 90.1%and 87.9% of coverage, respectively in 2010, 2011 and
2012. By using the samemodel, the complete schemewith 3rd dose reached 0%, 65.1% and 66.2% of coverage
status. Therewere observed a total of 430 local and systemic events in 360 subjects (36% of 1000 girls), strat-
iﬁedbyeachdose received.Noseriousadverseeventsoranyhospitalizationwere reported;Wealsoobserved
a reduction of about 55% in the incidence of genital warts in women under 21 years old.
Conclusion: A hybrid strategy for HPV proved to be effective in vaccinating adolescents in this municipality.
HPV vaccine was safe and effective in reducing genital warts, as demonstrated by international studies.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY license.Introduction
The human papillomavirus (HPV) is a sexually transmitted virus
with a high outcome of morbidity and mortality of cervical cancer
[1], accounting for about 275,000 deaths annually in women
worldwide [1].
In Brazil, a high percentage of the population is infected with
HPV, with an estimate of about 9–10 million of individuals infected,
producing an annual incidence of 17,540 new cases of cervical
cancer, responsible for 4000 deaths per year in the country [2].
HPV belongs to a heterogeneous family of more than 100
different genotypes. Among these genotypes, 40 of them can infect
the anogenital region [3]. They are classiﬁed in high-risk and
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and is associated with cancer of the cervix. HPV can produce
neoplastic changes known as intraepithelial cervical neoplasia
(CIN) grade I, II and III, related to the degree of dysplasia. They
are conﬁgured by lesions that lead to both cervical and uterine
carcinoma. Although HPV infection are of high incidence in young
women at early sexual activity, its worst outcome, in the form of
cervical cancer, is more common in women aged 40–60 years
old, given the long period of viral latency and evolution [4].
The main related HPV types of epidemiological importance are
types 16 and 18 (high risk), responsible for 70% of cases of cervical
cancer, and types 6 and 11 (low risk), which account for 90% of
cases of genital warts [5–7]. This virus can also be associated with
other types of cancer in addition to affecting the anogenital tract,
such as the cancer on the laryngeal, respiratory and digestive tracts
[8,9].
According to the portfolio of protection against HPV, the early
tracking with Pap screening associated with the use of condom
and also HPV vaccination are the current state of the art of preven-
tion. Quadrivalent (types 6, 11, 16, 18) and bivalent (types 16 and
18) vaccines against HPV are licensed nationally. Internationally
they are known as Gardasil (MSD) and Cervarix (GSK), respec-
tively [10]. As the highest incidence of infection occurs soon after
the onset of sexual activity, vaccination is recommended before
this period, which varies around 11 and 12 years of age. Printed
recommendations indicate vaccination from 9 years of age on-
wards [10]. According to the World Health Organization (WHO)
[11], the combination of strategies to increase coverage against
HPV associated with the most appropriate monitoring tools, will
set the base to reach the endpoint of reducing the incidence of
HPV related diseases.
It should be noted that HPV vaccines are not included in the
Brazilian National Immunization Program (NIP) and is only avail-
able in private clinics. Exceptionally, the city of Campos dos Goyt-
acazes, by using its own funds, included the quadrivalent vaccine
against HPV in the municipal vaccination calendar on September
13th, 2010, making it available for residents aged 11–15 years old.
This study aims to assess the effectiveness of the ‘‘hybrid’’ strat-
egy of HPV vaccination in Campos dos Goytacazes, using vaccina-
tion strategies in schools, at two ﬁxed sites as well as other
additional vaccination strategies. ‘‘Holidays HPV-free’’ was a
pioneering initiative targeted to girls, aiming to increase their
attendance to nearest Public Permanent Vaccination sites. Thus,
the objective was to assess through a survey, the vaccination cov-
erage against HPV, linked to a web-based tool for monitoring the
vaccination process. It is known that many successful programs
for HPV vaccination were implemented in developed countries,
but there is little literature available to demonstrate the effective-
ness of strategies in a city of a developing country like Brazil thus
demonstrating reduction of genital warts in young women.Methods
Characteristics of the city
The municipality of Campos dos Goytacazes is the largest city in
the state of Rio de Janeiro, Brazil, covering 4032 km2 of both urban
and rural areas. The population is estimated of 463,545 inhabitants
(240,000 of women) and is considered the largest metropolitan
area outside the state. Its economy is based on oil extraction, which
represents about 80% of the national production [12]. According to
data from the Brazilian Institute of Geography and Statistics (IBGE),
the population of girls of 11–15 years of age to be vaccinated is of
20.286, 20.479 and 20.661 of adolescents, respectively in 2010,
2011 and 2012.Epidemiological data from the municipality considered the an-
nual incidence of 30 cases of cervical cancer per 100.000 women.
There is an annual average of 15 deaths (7.5 per 100,000 women).
The Ministry of Health of Brazil consider the average incidence of
17 cases/100,000 women and 5 deaths/100,000 women.Design of pre vaccination strategy
The decision to offer the quadrivalent vaccine against HPV in
the municipality of Campos dos Goytacazes was made based on:
(i) realization of a ‘‘hybrid’’ strategy, (ii) refusal to vaccinate and
(iii) a cost-effectiveness survey, which was conducted prior to this
study.
Firstly, a ‘‘hybrid’’ strategy to combine mobile vaccination in
local schools and also in public permanent vaccination sites, from
Mondays to Fridays was carried out. This city houses 262 schools,
including public and private, distributed in all districts and rural
areas, bearing about 68 Public Clinics equipped with vaccination
rooms. The reason for choosing such strategy was based on the size
of the municipality and the number of schools.
This ‘‘hybrid’’ strategy was made possible thanks to the School
Health Program (PSE), a municipal strategy that brings together a
series of actions along with health services in schools in Campos
dos Goytacazes. Such initiative contributed with the municipal
vaccination strategy, which also included a series of lectures given
in public and private schools on HPV. Such lectures were rather
useful in elucidating issues of parents and adolescents.
Aiming to ﬁnd out the low attendance of girls to HPV vaccina-
tion, 300 parents were interviewed after the lectures. Results of
interviews helped in achieving vaccination events such as ‘‘D-
day’’ and ‘‘Holidays HPV-free’’.
A technical committee constituted by doctors and specialists as
well as public health experts designed a cost effectiveness model in
order to ensure that the cost of the vaccine would be lower when
compared to the treatment of genital warts and consequently the
risk of developing cervix cancer and other HPV-related diseases.Vaccination at school
Initially, with PSE’s collaboration, the professionals of the
County Immunization Coordination sent ofﬁcial letters to all
schools requesting the nominal list of girls aged 11–15 years old.
From 2011, when reaching the age of 11, the girls were referred
to vaccination. Vaccination routes involving schools from the same
district were scheduled. An informed consent term was sent to
each parent or guardian informing the beneﬁts of vaccination,
potential risks and an authorization term for carrying out
vaccination at schools.
Some weeks before September, 13th, 2010, the municipality
staff was trained to vaccinate in schools and public sites. This staff
consisted of 20 nurses and 10 members of the administrative staff,
who currently work in schools and health units. Moreover, they
were trained to insert the correct data information for coverage
concerns. So, vaccination data was inserted in a speciﬁc vaccina-
tion program database, named ‘‘SIVAC’’ which functions as an elec-
tronic vaccination notebook, informing when the next vaccination
routine for adolescents will be held. This system is available at
http://www.sivac.com.br.‘‘D-Day’’ vaccination
In November 2010 and 2012, two mobilization days (Saturdays)
were set in order to either update vaccination for girls who already
took the ﬁrst or second doses or to vaccinate girls who missed the
ﬁrst vaccination ‘‘D-Day’’. 500 nurses and 10 doctors to conduct the
interviews were recruited.
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During school holidays, the project ‘‘Holidays HPV-free’’ was
launched. Residents were invited to participate by various media,
informing that the vaccine would be available at local clinics. Such
strategy aimed to reach girls who did not yet received the ﬁrst or
the second dose of vaccine. Thus, each health unit could count with
health professionals (immunization teams) to offer the HPV
vaccine according to a pre-established schedule.
Permanent public sites for HPV vaccination
This strategy was implemented in order to attend parents and
guardians who did not have children at school and also to the ones
who delayed in sending the informed consent letter, preventing
their children to take part of the yearly vaccination calendar. For
this purpose, two vaccination rooms with trained staff were made
available to perform vaccination and provide information about
adverse events.
Calculation method of vaccination coverage
The calculation of HPV coverage was carried out using the
method described by Jose Cássio de Moraes and colleagues [13],
which imputes a ratio between the number of vaccinated and the
total number of individuals of the same age group. The female pop-
ulation used in the denominator was calculated for the years 2010,
2011 and 2012, according to IBGE [2]. They were inserted in the
numerator data vaccination for the ﬁrst and third doses (complete
scheme).
Survey of adverse events (quadrivalent HPV vaccine)
Authors conducted a survey of adverse events related to the
quadrivalent HPV vaccine. One thousand teenagers were randomly
selected, and were followed up after 96 h of vaccination to evaluate
safety and tolerability.
Quadrivalent HPV vaccine adverse events in the product mono-
graph are classiﬁed in: Most Common (>10%): irritability/pain, pyr-
exia, erythema, local edema; Less Common (>1% e <10%): diarrhea,
vomiting, myalgia, upper respiratory tract infection, cough, tooth-
ache, fever < 38.9 C, fever >38.9 C, malaise, arthralgia, nasal con-
gestion, insomnia; Serious adverse events (>0.01% e <0.1%): Pelvic
inﬂammatory disease, headache, appendicitis and gastroenteritis.
Evaluation of reduction in cases of genital warts
Since 2007 the municipality introduced a genital wart notiﬁca-
tion system, included in the National System of Notiﬁcation
(SINAN) of Brazilian Ministry of Health. Data are inserted in the
system by the public gynecology services and Infectious Disease
Centers. A survey on reduction of genital warts was conducted in
Campos dos Goytacazes before and after the introduction of the
vaccine using data from SINAN.
Results
From September 2010 to December 2012, about 90,000 doses of
HPV vaccine were used in the municipality.
We observed that about 13% of 300 parents interviewed refused
vaccination. Their reasons are listed in Fig. 1.
In Table 1, the cumulative coverage for each age is shown be-
low, considering the years 2010, 2011 and 2012. It also shows
methods used to calculate coverage and distribution age in each
year of interest.
It should be regarded that the 3rd HPV dose was not included in
2010, since the implementation of the quadrivalent vaccine started
in September, 2010, and results showed 0%.
The results shown in Fig. 2 considered the contribution of the
strategies used to achieve immunization coverage against HPV. Inthis sense, one should consider that the schools play a preponder-
ant role in bringing the girls to vaccination.
In Fig. 3, results of the most important adverse events related to
the quadrivalent HPV vaccine are presented. We observed a total of
430 local and systemic events in 360 subjects (36% of 1000 girls),
stratiﬁed by each dose received. No serious adverse events or any
hospitalization were reported. Results were close to those found
in product monograph.
One important outcome observed almost 3 years after the
beginning of vaccination using Data from the National System of
Notiﬁcation (SINAN) of the Brazilian Ministry of Health was ob-
served. Results showed in Fig. 4 ascertained that there was a signif-
icant reduction in the incidence of genital warts in women under
21 years old, with about 55% of reduction 2 years after the start
of vaccination in this municipality.Discussion
This is the ﬁrst study of a public Municipal Immunization
program carried out in Brazil using a survey of HPV vaccination
coverage and an efﬁcient hybrid strategy of vaccination carried
out in Campos dos Goytacazes, Brazil [14].
The vaccine was licensed in Brazil in June, 2006, and is available
in private vaccination clinics only. The municipality of Campos dos
Goytacazes made the vaccine available free of charges for the pop-
ulation of Campos dos Goytacazes in September 2010. Such initia-
tive has reached the mark of 80,000 doses from September 2010 up
to date for a population of about 20,000 youngsters [15] per year.
Thus, these results were compared with public vaccination strate-
gies performed in various countries around the world.
First, we highlight a hybrid school-based vaccination strategy
for the age group between 12 and 13 years beginning in 2007,
implemented by the Australian Government. At the same time,
additional catch-up strategies were drawn for adolescents aged
13–18 years (schools) and for women aged 19–26 years (vaccina-
tion posts). The ﬁndings of vaccination coverage strategy for the
three doses in the school program were respectively ﬁrst, second
and third doses in the order of 83%, 80% and 73%, respectively.
For the school-based catch-up strategy before 14–18 years, the
ﬁndings were in order of doses: 81–84%, 75–79% and 66–72%.
For the clinics strategy, aiming women of 19–26 years, the ﬁndings
were in order of doses: 52–64%, 42–53% and 30–38% [16–18]. In
relation to the reduction of incidence by about 90% of cases of
genital warts in men and women under 21 years of age [19,20],
important outcomes supported by statistical ﬁndings of no signif-
icant reduction in women older than 26 years of age and in men
who have sex with men [19,20] were achieved with this strategy.
Our study reached a coverage status similar to that one found in
Australia, except in 2010, when it reached a low coverage, mainly
because the vaccination campaign started in September 2010, thus
delaying the completion of vaccination scheme for that year.
Moreover, the vaccination strategy used in the United States,
based on vaccination centers, targeted to girls aged 11–12 years
of age, with a catch-up of 13–26 years of age was not as efﬁcient
in terms of coverage. Data from the CDC in Atlanta for HPV vacci-
nation in 2010–2011, showed that the coverage ranged from 32%
to 35% in the vaccination period with three doses [21]. When com-
pared to ours, this study holds strict differences, since in the USA,
the HPV vaccine is not offered in schools, only in private doctor’s
ofﬁces and medical clinics. In our study the vaccine was offered
free of charge. Vaccination against HPV has also been implemented
in Rwanda, Africa, by a national immunization strategy initiated in
2011 that combined a hybrid vaccination strategy in schools for
girls of the sixth grade of primary school, with a catch-up strategy
for girls of secondary education. From 2015, the vaccine will be
Fig. 1. Main reasons for refusal of the HPV vaccine in 13% of the 300 parents intereviewed.
Table 1
Quadrivalent HPV vaccine coverage among adolescents by dose and year of vaccination, Campos dos Goytacazes, Brazil.
2010 11 years (vg/pop = vc) 12 years 13 years 14 Years 15 years Total VC (%)
1st dose 1583/4083 = 38.7% 1695/3923 = 43.2% 2321/3969 = 58.4% 1930/4031 = 47.8% 3219/4280 = 75.2% 52.90%
3st dosea 0 0 0 0 0 0
2011 11 years (vg/pop = vc) 12 years 13 years 14 years 15 years Total VC (%)
1st dose 3756/4122 = 91.1% 3121/3960 = 78.8% 3948/4007 = 98.5% 3210/4069 = 78.8% 4231/4321 = 97.9% 89.02%
3st dose 2650/4122 = 64.2% 2054/3960 = 51.8% 3218/4007 = 80.3% 2430/4069 = 59.7% 2980/4321 = 68.9% 65.10%
2012 11 years (vg/pop = vc) 12 years 13 years 14 years 15 years Total VC (%)
1st dose 3680/4159 = 88.4% 3054/3996 = 76.4% 3890/4042 = 96.2% 3460/4105 = 84.2% 4087/4359 = 93.7% 87.90%
3st dose 2423/4159 = 58.2% 3112/3996 = 77.8% 2980/4042 = 73.70% 2646/4105 = 64.4% 2530/4359 = 58% 66.20%
Abbreviations: vg = vaccines given pop = adolescent population in the years 2010, 2011 vc = vaccination coverage and 2012.
a In 2010 there was not given the 3rd dose in any teen, because the implementation of the quadrivalent vaccine started in September, 2010.
Fig. 2. Strategies used to vaccination against HPV.
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sixth grade. Important ﬁndings of coverage with respect to the
strategy of mass media, lectures conveyed in schools and the asso-
ciation of the Ministries of Health and Education were achieved. By
using this strategy, so far, 93% of coverage for the three doses has
been achieved. For girls who were out of school and missed vacci-
nation day at school, vaccination was offered at basic health units
in order to achieve the values marked [1]. This contribution was
also viewed in our study, and we have concluded that the major
contribution to the HPV vaccine coverage status was assigned to
the schools, which represented 65% of all vaccines given.Another strategy concerns a public initiative of HPV vaccination
carried out in the province of Ontario, Canada in 2007–2008, direc-
ted to girls of 13 years of age, or before entering the ninth grade. In
this province, data analysis showed lower vaccination coverage,
despite vaccination carried out in schools. Thus, in the 2007–
2008 period, the coverage of the three doses was achieved in the
order of 51%; 58% in the 2008–2009 period; 54% in the period of
2009–2010 and of 59% in 2010–2011. These ﬁndings are related
to the lack of adequate monitoring coverage in health facilities
neighboring the schools where girls are vaccinated. The online vac-
cination system used (‘‘SIVAC’’) in our study prevented from loss of
relevant data, which was considered a problem in the study carried
out in Ontario [22].
This study presented some potential limitations. First, vaccina-
tion team had so many difﬁculties to achieve the vaccination cov-
erage status, mainly in the beginning of the strategy in 2010,
because of many reasons, which were: Little knowledge about
HPV; Lack or little knowledge about the HPV vaccine; the wide
geographical area bearing a large number of schools distributed
throughout its extent, including rural areas of difﬁcult access; a
need to increase the trained staff in order to ensure that all schools
would be visited in a running year; No prior initiatives of this
nature carried out in Brazil which made us learn from our own
mistakes; A need to convey health education in churches in order
to address controversial issues such as virginity and refusal to
Fig. 3. Quadrivalent HPV vaccine adverse events in campos dos Goytacazes, Brazil.
Fig. 4. Incidence of gential warts in women <21 years in the municipality of campos dos goytacazes, Brazil.
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resulting from this strategy depends on a number of successful
initiatives, which are: efﬁcient and adequate transport and storing
of samples; training of team on possible adverse reactions and
facilitate health education for parents and youngsters. Finally, we
consider the important contribution of the mass media in order
to expand the call for vaccination contributing to demystify some
misconceptions, which could help to increase the acceptance rate
of vaccination. Our study sought to use a hybrid approach that
combined a set of actions in order to implement a new type of vac-
cine within the Municipal Immunization Program, using the exist-
ing structure of public vaccination and taking into account the
need to keep all other strategies in order to maintain coverage
for vaccines mandatory of the National Immunization Program in
Brazil (NIP) [23].
According to our results, it seems evident that the good
coverage achieved by vaccination against HPV in Campos dos
Goytacazes, coupled with no serious adverse events to the vaccinereported throughout the study, point to the feasibility of this vac-
cination strategy, which can also be used in other municipalities.
Taking into account not only the beneﬁts but also the results with
regard to the reduction of genital warts, amply demonstrated by
international studies [18,19], we then seek to suggest the inclusion
of HPV vaccination in the Brazilian calendar.Funding source
Secretariat of Health of the Municipality of Campos dos
Goytacazes, Rio de Janeiro, Brazil.References
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